Panelists discuss how emerging, better-tolerated oral therapies for idiopathic pulmonary fibrosis (IPF) and progressive ...

Currently available treatments for IPF are limited to only two approved drugs that come with significant side-effects, ...

Panelists discuss recent trial data demonstrating that a novel agent not only slows lung function decline but also delays ...

Pulmonary rehabilitation is initiated and completed by a greater proportion of patients with IPF vs COPD or other chronic respiratory disorders.

Pliant Therapeutics has terminated its idiopathic pulmonary fibrosis (IPF) program after digging into the increased rate of ...

DelveInsight's NADPH Oxidase (NOX)-Replacement Therapies Market Size, Target Population, Competitive Landscape & Market ...

The website you are visiting is protected and accelerated by Imperva. Your computer may have been infected by malware and ...

Pliant Therapeutics has discontinued development of bexotegrast in idiopathic pulmonary fibrosis following a review from a recently terminated clinical trial. "We believe it is the right decision to ...

The University of Texas at Tyler was awarded a $219,000 grant to help fund a professor’s pulmonary fibrosis treatment project ...

A trial using PET scans to test the anti-inflammatory drug PIPE-791 finished enrolling healthy volunteers and patients with ...

Diversified Trust Co bought a new position in Trevi Therapeutics, Inc. (NASDAQ:TRVI – Free Report) during the first quarter, ...

Advanced lab-grown tissues help show how special lung cells develop, shedding light on rare ACDMPV disease and suggesting potential ways to repair damage from viral infections such as COVID-19 ...